Tag Archives: eoe

My EoE Journey: From Misdiagnosis to Management and Motherhood

I was in my early twenties, freshly out of college, when I experienced something that would quietly but profoundly alter the course of my life. I was sitting at my cubicle, working as a Marketing Assistant, when I choked on a sip of water. Not food—water. It seemed strange but harmless at the time. A fluke, maybe. But soon, the choking started happening more frequently. Sometimes it was food, sometimes liquid, and each time I felt the same wave of confusion and rising panic. Something was not right.

In those early days, I had no idea what eosinophilic esophagitis (EoE) even was. I bounced from one healthcare system to another, desperate for answers. Each provider had a theory—acid reflux, GERD, ulcers (they said my stomach looked like a battlefield). I was prescribed PPIs and told to monitor my diet, and to be honest, I was in my twenties and refused to do a full elimination diet. Nor did I have the income to have an endoscopy done every three or so months. The episodes didn’t stop. My esophagus felt like a mystery organ—failing me and evading every explanation.

It wasn’t until I underwent multiple endoscopies that I finally received a diagnosis: eosinophilic esophagitis. Relief washed over me at first. I had a name for the thing disrupting my life. I was prescribed a steroid inhaler (used off-label to coat the esophagus), which I was hopeful about—but it failed to make a meaningful difference.

Getting that diagnosis also brought something else: anxiety. More than just the fear of choking was the fear of food itself. Every meal became a potential minefield. I started to dread eating in public, afraid of making a scene if something got stuck. I’d chew excessively, avoid certain textures, and sometimes skip meals altogether. The anxiety around food slowly became as overwhelming as the disease. I thought, “This is my life forever?!”

Professionally, I work in clinical trial technology, and my experience gave me a unique perspective on how new treatments are developed. So, when the chance came to join a clinical trial for EoE, I didn’t hesitate. I wanted to be part of something bigger — advancing the science that might help me and others like me. I enrolled in my first clinical trial with optimism.

Unfortunately, despite having active EoE, I didn’t qualify. The trial required a certain eosinophil count in three biopsy locations, and one of mine didn’t meet the threshold. It was disheartening. I had hoped for progress, but I felt stalled—once again at the mercy of a disease that didn’t fit neatly into diagnostic boxes.

Determined not to give up, I enrolled in a second trial. This one showed more promise, and I was actively participating for several months. But clinical trials aren’t easy. There are what we call “patient burdens”—logistics, check-ins, tracking symptoms, and in my case, commuting into the city. At one point, due to a device malfunction and some technical logging issues, I missed a week of entries. That small lapse disqualified me from continuing. I understood the importance of adherence in trials, but the reality of juggling life, work, and health made it incredibly challenging. It was an emotionally draining setback.

I was 32 when I finally tried a biologic for EoE – dupilumab. And almost immediately, for the first time since my diagnosis, I went into remission. The choking stopped. I could eat again—carefully, but freely. For the first time in years, I felt like I could breathe, metaphorically and literally.

In 2022, I became pregnant with my first child. Dupilumab had been my lifeline, but there wasn’t enough data on its use during pregnancy. After discussing with my doctor, we decided I’d stop taking it. Interestingly, my EoE symptoms went away during pregnancy. My doctor had mentioned that this was common—pregnancy hormones can suppress symptoms—and in my case, it was true. I had a smooth pregnancy, symptom-free. But three months postpartum, everything changed. I had my first choking episode since stopping the biologic. It was a wake-up call. I restarted the medication under medical supervision. Again, I wanted to continue breastfeeding, but there was little research on the medication during lactation. I pushed it as long as I could without the medication, but my symptoms—especially food impaction—became impossible to ignore.

Fast forward to 2024, when I had my second baby. Once again, pregnancy offered a strange relief—no symptoms at all. But just like last time, three months postpartum, the EoE came roaring back. One particularly terrifying episode involved food and water getting stuck for over 30 minutes. I started making arrangements for child care just so I could go to the ER. I was choking multiple times a week. It wasn’t just disruptive—it was terrifying. At that point, I had no choice. I had to go back on the medication, even while breastfeeding. My well-being had to come first. Since the very first injection, I haven’t choked since.

My most recent endoscopy showed that my esophagus couldn’t be dilated to the full amount—it had narrowed from years of inflammation and scarring—but the inflammation is now under control. On dupilumab, I’m living a normal life again. I can sit down at dinner with my husband and kids and not fear the worst. I can be present for my son and daughter, rather than worried I might end up in the ER.

Still, it’s hard not to reflect on how long it took to get here. The road was exhausting—full of trial and error, emotional tolls, and moments of genuine fear. Choking doesn’t just affect your throat—it affects your confidence, your mental health, and your relationship with the world around you. I’ve missed meals, missed moments, and lived with the kind of hypervigilance that only chronic illness can teach you.

Even now, I don’t consider my journey over. The weekly injection I take is a constant reminder that I’m managing something, not defeating it. I still hope for better treatments, for real remission, and one day, a cure. I’m committed to staying involved in research and advocating for more data—especially for women who want to become or are already mothers. We need more research on EoE during pregnancy and breastfeeding. We deserve to make informed choices, backed by science.

EoE is often invisible to the outside world. You can look perfectly fine while suffering internally. That’s why I share my story—because someone out there might be having their first choking episode and wondering what’s wrong. Someone might be navigating postpartum life, unsure of what symptoms to expect. Someone might be weighing treatment options or joining a clinical trial.

To those people: you’re not alone. EoE is complicated, misunderstood, and underdiagnosed—but it’s manageable. With the right care, with persistence, and with continued research, there’s hope.

If you’re living with EoE, or suspect you might be, trust your body and keep advocating for yourself. It took me a decade to get from confusion to control. I hope your journey is shorter—but even if it’s not, know that there’s a path forward.

And to the researchers, clinicians, and trial coordinators out there: thank you. Your work matters. You’re changing lives—one patient, one injection, one study at a time.

Jessica recently spoke at APFED’s 2025 All-virtual Research Round Up to discuss her experiences with clinical trials for EoE. A clip of the interview is below:

Jessica Grady is a B2B marketing leader with a strong background in life sciences and SaaS. With expertise in marketing operations, customer marketing, and demand generation, she brings both strategic insight and empathy to her work. Her personal experience as a clinical trial participant fuels her passion for improving the patient experience in research. Jessica holds a master’s degree in marketing and lives outside Philadelphia with her husband, Matt, and their two children. She enjoys spending time with family and friends — especially around a good meal (when she’s not avoiding her EoE trigger foods).

 

EoE Awareness on the Move: APFED’s National Transit Campaign Launches

We’re proud to announce the launch of APFED’s first nationwide awareness campaign for eosinophilic esophagitis (EoE), now live in San Diego and rolling out across the country in 2025!

This historic effort marks a significant milestone for the EoE community. This often-overlooked and misunderstood disease is receiving the large-scale public visibility it deserves. Through striking billboards, digital transit ads, and online engagement, we’re sparking vital conversations about EoE—starting with its most common symptoms.

An estimated 1 in 700 Americans lives with EoE, yet many go years without an accurate diagnosis. Our campaign aims to change that by educating the public about symptoms and encouraging individuals to speak with their doctors. It builds on the momentum of our Nasdaq billboard campaign in Times Square in New York City last year and is now reaching communities nationwide.

Where You’ll See Our Campaign

Airport Digital Displays:

  • Denver Int’l Airport – Sept. 8 – Oct. 5
  • Chicago Midway Airport – Oct. 27 – Nov. 23
  • Chicago O’Hare Airport – Oct. 27 – Nov. 23
  • Baltimore/Washington Int’l Airport  – June 30 – July 27

Mass Transit:

  • Boston’s MBTA Subway Red & Green Lines – October (dates TBD)
  • Orlando’s Brightline high-speed rail – Nov. 3-28
  • Anaheim pedestrian kiosks – Dates TBD

Help Us Amplify the Message
We invite you to join us in spreading awareness. If you see one of our ads in your city:

  1. Snap a photo
  2. Share it on social media with #APFEDEoE
  3. Tag your location

Each share helps raise awareness, spark earlier diagnoses, and improve care for those living with EoE. Together, we’re shining a light on this often-overlooked disease. Stay tuned—our campaign is just getting started as it rolls out nationwide!

We are grateful to Sanofi, Regeneron, and Takeda for their generous support in helping APFED bringing this national awareness campaign to life and helping to shine a  spotlight on EoE!

APFED to Honor World EoE Day, May 22

On May 22, 2025, the global community will recognize the first-ever  World Eosinophilic Esophagitis (EoE) Day—a significant milestone in raising awareness about this chronic and often misunderstood condition.

Eosinophilic esophagitis (EoE) is a chronic disease in which eosinophils (a type of white blood cell) build up in the esophagus, leading to inflammation, difficulty swallowing, and other complications. EoE can significantly impact a patient’s quality of life, especially when left undiagnosed or untreated.

Despite its increasing prevalence, EoE remains underdiagnosed and frequently misunderstood, leading to delayed treatment for many patients. World EoE Day aims to bridge this gap by raising public awareness of symptoms and encouraging healthcare consultation, and advocating for better care and treatment.

World EoE Day is spearheaded by the EoE Day Alliance, a partnership of patient organizations dedicated to improving awareness and support for those affected by EoE. Members of the alliance include:

  • AEDESEO – Asociación de Pacientes con Déficit de Eosinófilos y Síndrome Eosinofílico de Origen Desconocido (Spain)
  • APFED – American Partnership for Eosinophilic Disorders (USA)
  • ausEE Inc. – An organization dedicated to supporting those affected by eosinophilic diseases (Australia)
  • ESEO Italia – Associazione di famiglie contro l’esofagite eosinofila e le patologie gastrointestinali eosinofile (Italy)
  • FAACT – Food Allergy & Anaphylaxis Connection Team (USA)
  • GAAPP – Global Allergy and Airways Patient Platform (Austria)
  • Nacionalno udruženje EOE – Više od alergije (Serbia)

“Raising awareness about eosinophilic esophagitis is critical to ensuring early diagnosis and access to appropriate care,” said APFED Executive Director Mary Jo Strobel in a press release issued by GAAPP on behalf of the Alliance. “Too many patients endure years of symptoms before receiving answers. By increasing understanding among healthcare providers and the public, we can reduce delays in recognition and diagnostics, improve outcomes, and enhance the quality of life for those affected by this chronic condition.”

In the coming weeks, the EoE Day Alliance will be developing resources in a variety of languages to be made freely available to all those wishing to join our efforts to raise global awareness of EoE. We’ll post related announcements regarding the availability of new resources to this website (apfed.org) and to APFED’s social media channels when they are available.

World EoE Day will take during National Eosinophil Awareness Week this year, as will World Eosinophilic Diseases Day, which is honored annually on May 18.

###

  • Could it Be EoE? If you suspect you or a loved one might have EoE, we encourage you to download this guide and speak to a healthcare provider about symptoms you are experiencing.

 

APFED Partners with “Viewpoint with Dennis Quaid” to Spotlight EoE in Nationwide TV Segment

FOR IMMEDIATE RELEASE

APFED Partners with Viewpoint with Dennis Quaid to Spotlight Eosinophilic Esophagitis (EoE) in Nationwide TV Segment

Atlanta, GA – January 7, 2025 – The American Partnership for Eosinophilic Disorders (APFED) is thrilled to announce its collaboration with Viewpoint with Dennis Quaid, a trusted platform for thought-provoking discussions and educational content. Together, APFED and Viewpoint will bring national attention to eosinophilic esophagitis (EoE), a chronic immune condition affecting the esophagus.

This full segment explores EoE, shedding light on the experiences of those living with this complex condition. Through this initiative, APFED aims to raise awareness, encourage viewers to recognize symptoms in themselves or loved ones, and inspire meaningful conversations with healthcare providers.

APFED is dedicated to improving the lives of individuals affected by eosinophil-associated diseases through education, advocacy, support, and research. The segment underscores the importance of a collaborative, informed community in driving innovation and improving outcomes for patients.

The national airing of clips from the documentary begin January 8, 2025, on Fox Business Network during primetime (estimated airtime 6:30pmET, but could vary by an hour). Additional broadcasts will follow on major networks, including CNN, MSNBC, CNBC, Discovery Life, Family Channel, and CNN Headline News, with availability throughout the year.

“We are excited to collaborate with Viewpoint with Dennis Quaid to bring EoE into focus,” said APFED Executive Director Mary Jo Strobel. “This partnership represents an incredible opportunity to educate the public, support the EoE community, and advocate for early diagnosis and effective care.”

The full documentary may be viewed online at https://www.viewpointproject.com/features-apfed/.

Funding for this campaign was made available thanks to a grant from Sanofi and Regeneron. For more information about APFED and its mission, visit www.apfed.org.

About APFED
The American Partnership for Eosinophilic Disorders (APFED) is a nonprofit organization that supports families affected by eosinophil-associated diseases. APFED works to educate, advocate, and fund innovative research to improve the lives of those with these chronic conditions.

 

ACG Annual Scientific Meeting & Postgraduate Course 2024

The American College of Gastroenterology (ACG) hosted its Annual Scientific Meeting & Postgraduate Course in Philadelphia, Oct. 25-30, 2024. ACG is a recognized leader in educating GI professionals and the general public about digestive disorders.

During the conference, attendees had the opportunity to participate in a number of sessions to further their understanding of eosinophilic GI disease, including clinical presentation, evaluation, and treatment of eosinophilic gastrointestinal disorders based on current evidence.

Attendees visited the APFED booth in the exhibit hall to pick up educational materials to share with their patients and to learn about professional resources, and to chat with us about the needs of patients.

Other meeting highlights are as follows:

  • A session on esophageal disorders was hosted and included EoE and updates from the ACG Guidelines which are expected be published in early 2025. See this interview with Dr. Evan Dellon posted to the Gastroenterology Learning Network who summarizes the guidelines.
  • Sanofi and Regeneron (makers of Dupixent® (dupilumab), a biologic approved in the U.S. to treat EoE) sponsored a number of special learning opportunities that spotlighted EoE, including two Product Theaters and a Satellite Symposium. Product theaters discussed how and why EoE management strategies should evolve as our understanding of disease pathogenesis grows. The other showcased how inhibiting two key cytokines can impact disease and the efficacy and safety of a treatment option. The Satellite Symposium equipped clinicians with the knowledge and skills necessary to optimize diagnosis and management of EoE in pediatric and adult patients. There were also several posters presented on dupliumab.
  • The findings from a phase 3 clinical trial for a potential EoE treatment called cendakimab (a biologic being developed by Bristol-Myers Squibb) were presented. Read more in our blog post here.
  • The local tolerability and efficacy of an extended release formulation of fluticasone (EP-104GI) to potentially treat EoE were presented as posters.

Many research posters related to eosinophilic GI disease were also presented throughout the conference. Just few highlights from the poster session are below. To access all of the posters, visit https://acgposters2024.eventscribe.net/

  • “Prevalence and Costs of Eosinophilic Esophagitis in the United States” is research that reports prevalence of EoE continues to rise rapidly in the United States. In 2022, the prevalence was estimated at 1 in 617 for those under 65 years old, and 1 in 1,562 for those 65 and older. When standardized to the overall U.S. population, the estimated prevalence is around 1 in 700 people. This represents a substantial 5-fold increase since 2009. The rising prevalence of EoE has led to a significant financial burden, with estimated annual healthcare costs reaching $1.32 billion in 2024. Given EoE’s growing prevalence and impact, it is now considered a commonly encountered condition that should be considered for patients with upper gastrointestinal symptoms.
  • “No Association Between Eosinophilic Esophagitis and Esophageal Cancer in United States Adults: A Case Control Study Co-incidence of EoE” described findings from one study cohort that EoE is not associated with development of esophageal cancer.
  • “Predictive Artificial Intelligence Analysis of Determinants of Health Outcomes in Hospitalized Patients with Eosinophilic Esophagitis” aimed to use predictive AI to look at factors that influence health outcomes of those hospitalized for EoE, highlighting the potential of AI to help healthcare providers allocate resources,
  • A number of posters about dupilumab (Dupixent®) were presented including favorable results from the Phase 3 KIDS study that assessed efficacy of this drug in children ages 1-12 years with improvements of histologic and endoscopic aspects of EoE up to week 52. Another poster, “Efficacy and Safety of Dupilumab in Patients With Eosinophilic Esophagitis: Pooled Analysis and a Systematic Review” explores the current research on dupilumab in EoE, presenting key findings from available studies suggesting this drug effectively induces histological remission and improves clinical outcomes in EoE patients. The safety profile appears favorable when compared to placebo, with low rates of total and serious adverse events.
  • “Exploring Demographic Variations in Eosinophilic Esophagitis: A Nationwide Study of Hospital Admissions From 2019-2023” highlights important racial and gender disparities in the incidence of eosinophilic esophagitis (EoE). Higher prevalence among White and Black populations compared to other racial groups suggests potential genetic or environmental factors may influence EoE risk, and the findings underscore the need for healthcare strategies that are tailored to specific patient populations to improve treatment outcomes and efficacy in managing this condition.
  • “Unmet Needs Among Patients with Eosinophilic Esophagitis Despite Biologic Use” describes a real-world analysis looked at patients with Eosinophilic Esophagitis (EoE) who use biologic medications as their main treatment. Even though the biologics improved their symptoms, the analysis found that most patients still had to adapt their eating behaviors.
  • “Risk of Barrett’s Esophagus in Eosinophilic Esophagitis: A Multi-Center Research Network Analysis” utilized a multi-institutional network to assess BE risk in individuals with EoE and found a higher risk of BE in patients with EoE in their study cohort.
  • “Understanding the Current State of Eosinophilic Esophagitis Research: Insights from ClinicalTrials.gov” reported the research landscape on Eosinophilic Esophagitis (EoE) is diverse, but heavily leans towards interventional studies, especially those exploring pharmacological interventions. The data also highlights an underrepresentation of federally funded research in the field. Given the prevalence of ongoing studies, this analysis serves as a valuable resource for clinicians, researchers, and policymakers engaged in EoE research and treatment.
  • Role of TSLP in an Experimental Mouse Model of Eosinophilic Esophagitis” TSLP contributes to inflammation in Eosinophilic Esophagitis (EoE). When researchers induced EoE in mice, TSLP levels increased in the esophagus. To test TSLP’s importance, researchers gave the mice an antibody to block TSLP. This reduced the number of inflammatory cells (eosinophils) in the esophagus by 60%. It also decreased other signs of EoE, like thickening of the esophagus lining. These results suggest TSLP plays a key role in driving the inflammation and tissue changes seen in EoE. Targeting TSLP could lead to new treatment approaches for patients in the future.
  • “Family History of Eosinophilic Esophagitis or Other Eosinophilic Gastrointestinal Disease Is Not Associated With Non-Response to Topical Steroid Treatment in Eosinophilic Esophagitis.” This study examined whether clinical features or topical steroid treatment response differed between eosinophilic esophagitis (EoE) patients with and without a family history of EoE or other eosinophilic gastrointestinal diseases (EGID). In summary, they found that while EoE patients with a family history showed some initial presentation differences, family history itself did not emerge as a major risk factor for treatment outcomes.
  • “Seasons of Eosinophilic Esophagitis: Pinpointing the Summer Summit of Exacerbations” This study found significant seasonal variation in eosinophilic esophagitis (EoE) presentations, with a peak during summer months. These findings suggest aeroallergens may exacerbate EoE, highlighting the importance of considering seasonal allergen exposure when managing EoE in adult patients.
  • “Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis” described the potential role of dupilumab in facilitating introduction of EoE trigger foods. Researchers conducted an open-label pilot study that evaluated the use of dupilumab in 21 patients with food-triggered eosinophilic esophagitis (EoE). Participants received dupilumab alongside standard EoE therapy and elimination of their trigger food, followed by a 12-month food reintroduction process. Dupilumab enabled the reintroduction of EoE trigger foods without exacerbating symptoms or compromising histological and endoscopic outcomes, effectively controlling symptoms, preserving histologic integrity, and preventing endoscopic progression. This suggests dupilumab has the potential to reduce the burden of dietary restrictions for EoE patients, thereby enhancing their quality of life.
  • “Predictors of Patients Receiving No Medication for Treatment of Eosinophilic Esophagitis in the United States: Data from the TARGET-EGIDS Cohort” describes a real-world analysis to evaluate predictors for absence of recorded medications and prescriptions prior to or following an initial EoE diagnosis. Among newly diagnosed patients with EoE, ~1 in 10 had no recorded pharmacologic therapy. Older patients and those without complications were more likely not to receive a medication for EoE. Further evaluation, including whether alternative treatments were used and outcomes, is warranted for this group.
  • “Gastroparesis in Patients With Eosinophilic Gastrointestinal Diseases is Associated With Increased Symptoms and Comorbid Conditions” In a study analyzing 526 participants from EGIDPartners.org (402 with EoE and 124 with non-EoE EGID), researchers found that 8% of participants had gastroparesis (GP), which is significantly higher than the 0.16% prevalence in the general U.S. population. GP was more prevalent in non-EoE EGID patients (16%) compared to EoE patients (5%), and patients with GP experienced increased symptoms including chest pain, abdominal pain, nausea, vomiting, and constipation. The study also revealed that EGID patients with GP were more likely to have atopic disorders (such as eczema and food allergies) and autoimmune or connective tissue disorders (like Raynaud’s and Ehlers Danlos syndrome). While the findings suggest a potential relationship between these conditions, further research is needed to establish a direct connection between EGIDs and gastroparesis.
  • “Effect of Budesonide Oral Suspension on Dysphagia Symptom Outcomes in Patients With Eosinophilic Esophagitis: A Pooled Post Hoc Analysis of Data From a Phase 2 and a Phase 3 Trial” This post hoc analysis of pooled data from phase 2 and 3 studies examined the efficacy of budesonide oral suspension (BOS) 2.0 mg twice daily versus placebo in 410 patients with eosinophilic esophagitis (EoE). Using an adapted methodology to analyze Dysphagia Symptom Questionnaire (DSQ) scores, the study found that patients treated with BOS (n=263) showed significantly greater improvements in both 14-day and 7-day prorated DSQ scores compared to placebo (n=147) at weeks 4, 8, and 12 of therapy. The treatment groups had similar baseline scores, but BOS-treated patients demonstrated significant symptom improvement as early as week 4. These findings, consistent with the prespecified analysis, reinforce the effectiveness of BOS 2.0 mg twice daily in managing dysphagia symptoms in EoE patients over a 12-week treatment period.

 

Learn more about the 2024 ACG Annual Scientific Meeting & Postgraduate Course at acgmeetings.gi.org.